Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Hospitalier Universitaire de Nīmes
The secondary objectives of this study include:
A. To compare the following elements between the two patient groups:
* the number of CMCs per ml of blood as determined by EPISPOT
* the number of CMCs per ml of blood as determined by CellSearch
* the percentage of patients with at least 2 CMCs per ml of blood according to the two techniques
* the % of CMCs expressing KI67
* the % of CMCs expressions S100 (only the EPISPOT technique)
B. To compare the EPISPOT and CellSearch techniques is terms of the following:
* the number of CMCs detected per ml blood
* the number of CMCs expressing antigen KI67
C. To re-evaluate the 2-CMC per ml blood threshold
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient must have given his/her informed and signed consent
The patient must be insured or beneficiary of a health insurance plan
The patient is available, within the hours of his/her normally scheduled medical care, for blood sampling at 8 am and 4 pm on the same day.
Stage 4 melanoma, without other associated neoplasms
Patient without cancer, nor history of cancer
You may not be if
The patient is participating in another study
The patient is in an exclusion period determined by a previous study
The patient is under judicial protection, under tutorship or curatorship
The patient refuses to sign the consent
It is impossible to correctly inform the patient
The patient is pregnant, parturient, or breastfeeding
The patient has a contra-indication for a treatment used in this study
Stage 1 to 3 melanoma, or other types of cancer
History of cancer
Clareo Health | Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques
